Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brl 26830a
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
01
Overview
BRL 26830A is a beta-adrenoceptor agonist with high selectivity for thermogenesis, developed as an antiobesity agent. It acts primarily as a beta-3 adrenergic receptor agonist, increasing metabolic rate and promoting weight loss by enhancing fat metabolism. Clinical studies have shown that it can significantly increase weight loss in obese subjects on a restricted diet compared to placebo, with the majority of weight loss attributed to adipose tissue reduction. The drug was originally developed by SmithKline Beecham (now GSK). Common adverse effects include mild tremor due to skeletal muscle beta-2 adrenoceptor activation[1][2][3].
02
Targets
ADRB3 (β3)ADRB2 (β2)
Beyond the preview
Go deeper on brl 26830a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brl 26830a.